Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application...( BETHESDA Md. April 2 /- Micromet Inc....),Health

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million Euro (US$ 2.0 million) from Nycomed for the achievement of this milestone.

Under a 2007 agreement between the two companies, Micromet and Nycomed are developing MT203, a human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases. Preclinical studies support development of MT203 for the treatment of rheumatoid arthritis and several other diseases, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.

"Since the start of our collaboration with Nycomed in 2007, we have made excellent progress on the preclinical development of MT203," said Jens Hennecke, Micromet's Senior Vice President of Business Development. "The filing of the CTA represents an important milestone and we are looking forward to the start of clinical trials with MT203."

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells.
'/>"/>